Author

Alfred Zippelius

University of BaselORCID 0000-0003-1933-8178Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:scRNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:ATAC-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

Andreas ZinggiD· 4 shared Mascha BinderiD· 4 shared Heinz Philipp LaubliiD· 3 shared Michael T. SandholzeriD· 3 shared Andreas HolbroiD· 2 shared Christoph SchultheißiD· 2 shared Clara SergeriD· 2 shared Helen ThutiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

Andreas ZinggORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ImmunologybioRxivPreprintAug 6, 2026

alpha2,3-sialylation on human naive T cells restrains bispecific engager-mediated anti-tumor immunity

Johanna Nimmerfroh, Dinah Heiligensetzer, Michael T. Sandholzer…·Heinz Philipp Laubli

Desialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

DOI 10.64898/2026.08.02.742298

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 23, 2025

Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma

Michael T. Sandholzer, Clara Serger, Alessia G Liner…·Heinz Philipp Laubli

This study profiles tumor-reactive T cell dynamics during TIL therapy in metastatic melanoma, identifying factors associated with response and resistance.

DOI 10.1101/2025.09.23.678066

𝕏 PostBluesky

ImmunologybioRxivPreprintAug 26, 2025

CD39 defines a cytotoxic tumor-associated NK cell state responsive to NKG2A blockade in lung cancer

Clara Serger, Lucas Rebuffet, Michael T. Sandholzer…·Alfred Zippelius

The paper identifies CD39+ tumor-associated NK cells as a cytotoxic effector state in NSCLC responsive to NKG2A blockade through multiomic analysis.

DOI 10.1101/2025.08.26.672316

𝕏 PostBluesky

Cancer BiologyCancer Immunology ResearchPeer-reviewedApr 16, 2025

Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers

Andreas Zingg, Reto Ritschard, Helen Thut…·Heinz Philipp Laubli

This study develops a fully human CAR-T cell therapy targeting the STn antigen, showing activity in preclinical models of gastro-intestinal and gynecological cancers.

10 citationstop 5%

mouseproteomics

𝕏 PostBluesky

Alfred Zippelius · henhao